Αποτελέσματα αναζήτησης - "ЗЛОКАЧЕСТВЕННЫЕ ОПУХОЛИ"

Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 18, No 3 (2025); 365-375 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 18, No 3 (2025); 365-375 ; 2070-4933 ; 2070-4909

Θεματικοί όροι: диагностика, computer vision, convolutional neural networks, visual transformers, image classification, melanoma, benign neoplasms, malignant neoplasms, diagnosis, компьютерное зрение, сверточные нейронные сети, трансформеры, классификация изображений, меланома, доброкачественные опухоли, злокачественные опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/1256/635; Schaumburg F., Berli C. Challenges and proposed solutions for optical reading on point-of-need testing systems. Front Sensors. 2023; 4. https://doi.org/10.3389/fsens.2023.1327240.; Visalini S., Kanagavalli R. A comprehensive survey of pneumonia diagnosis: image processing and deep learning advancements. In: 2023 3rd International Conference on Innovative Mechanisms for Industry Applications (ICIMIA). https://doi.org/10.1109/ICIMIA60377.2023.10426403.; Prabha S., Gupta S., Pandey S.P. Deep learning for medical image segmentation using convolutional neural networks. In: 2024 International Conference on Optimization Computing and Wireless Communication (ICOCWC). https://doi.org/10.1109/ICOCWC60930.2024.10470841.; Das M., Sambodhi P.P., Khare A., Naik S.A. Challenges of medical text and image processing. In: 2022 International Conference on Advancements in Smart, Secure and Intelligent Computing (ASSIC). https://doi.org/10.1109/ASSIC55218.2022.10088402.; Choudhury S., Gowri R., Babu Sena P., Dinh-Thuan D. (Eds) Intelligent Communication, Control and Devices Proceedings of ICICCD 2020: Proceedings of ICICCD 2020. https://doi.org/10.1007/978-981-16-1510-8.; Ламоткин А.И., Корабельников Д.И., Ламоткин И.А. и др. Искусственный интеллект в здравоохранении и медицине: история ключевых событий, его значимость для врачей, уровень развития в разных странах. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2024; 17 (2): 243–50. https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.254.; Ламоткин А.И., Корабельников Д.И., Ламоткин И.А. и др. Точность предварительной диагностики злокачественных меланоцитарных опухолей кожи с помощью программы искусственного интеллекта Melanoma Check. Медицинский вестник Главного военного клинического госпиталя им. Н.Н. Бурденко. 2025; 1: 42–51. https://doi.org/10.53652/2782-1730-2025-6-1-42-51.; Zhou Z., Jin Y., Ye H., et al. Classification, detection, and segmentation performance of image-based AI in intracranial aneurysm: a systematic review. BMC Med Imaging. 2024; 24 (1): 164. https://doi.org/10.1186/s12880-024-01347-9.; Корабельников Д.И., Ламоткин А.И. Эффективность применения искусственного интеллекта в клинической медицине. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2025; 18 (1): 114–24. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.287.; Alzubaidi L., Zhang J., Humaidi A.J., et al. Review of deep learning: concepts, CNN architectures, challenges, applications, future directions. J Big Data. 2021; 8 (1): 53. https://doi.org/10.1186/s40537-021-00444-8.; LeCun Y., Bengio Y., Hinton G. Deep learning. Nature. 2015; 521: 436–44. https://doi.org/10.1038/nature14539.; Ламоткин А.И., Корабельников Д.И., Ламоткин И.А. Предварительная дифференциальная диагностика доброкачественных и злокачественных опухолей из эпидермальной ткани кожи с применением программы искусственного интеллекта «Derma Onko Check». Современные проблемы здравоохранения и медицинской статистики. 2025; 2: 223–42. https://doi.org/10.24412/2312-2935-2025-2-223-242.; Ламоткин А.И., Корабельников Д.И., Олисова О.Ю., Ламоткин И.А. Эффективность предварительной дифференциальной диагностики доброкачественных и злокачественных новообразований кожи с помощью программы искусственного интеллекта Derma Onko Check. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2025; 18 (2): 261–70. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.294.; Milletari F., Ahmadi S.A., Kroll C., et al. Hough-CNN: deep learning for segmentation of deep brain regions in MRI and ultrasound. Computer Vision Image Underst. 2017; 164: 92–102. https://doi.org/10.48550/arXiv.1601.07014.; Yamada M., Saito Y., Imaoka H., et al. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. Sci Rep. 2019; 9 (1): 14465. https://doi.org/10.1038/s41598-019-50567-5.; Yadav D., Rathor S. Bone fracture detection and classification using deep learning approach. In: 2020 International Conference on Power Electronics & IoT Applications in Renewable Energy and its Control (PARC). https://doi.org/10.1109/PARC49193.2020.236611.; Rahman T., Chowdhury M.E., Khandakar A., et al. Transfer learning with deep convolutional neural network (CNN) for pneumonia detection using chest X-ray. Appl Sci. 2020; 10 (9): 3233. https://doi.org/10.3390/app10093233.; Hamamoto R., Suvarna K., Yamada M., et al. Application of artificial intelligence technology in oncology: towards the establishment of precision medicine. Cancers. 2020; 12 (12): 3532. https://doi.org/10.3390/cancers12123532.; Asada K., Kobayashi K., Joutard S., et al. Uncovering prognosisrelated genes and pathways by multi-omics analysis in lung cancer. Biomolecules. 2020; 10: 524. https://doi.org/10.3390/biom10040524.; Kobayashi K., Bolatkan A., Shiina S., Hamamoto R. Fully-connected neural networks with reduced parameterization for predicting histological types of lung cancer from somatic mutations. Biomolecules. 2020; 10 (9): 1249. https://doi.org/10.3390/biom10091249.; Takahashi S., Asada K., Takasawa K., et al. Predicting deep learning based multi-omics parallel integration survival subtypes in lung cancer using reverse phase protein array data. Biomolecules. 2020; 10 (10): 1460. https://doi.org/10.3390/biom10101460.; Takahashi S., Sakaguchi Y., Kouno N., et al. Comparison of vision transformers and convolutional neural networks in medical image analysis: a systematic review. J Med Syst. 2024; 48 (1): 84. https://doi.org/10.1007/s10916-024-02105-8.; Selvaraju R.R., Cogswell M., Das A., et al. Grad-CAM: visual explanations from deep networks via gradient-based localization. In: 2017 Proceedings of the IEEE international conference on computer vision. https://doi.org/10.48550/arXiv.1610.02391.; Takahashi S., Takahashi M., Kinoshita M., et al. Fine-tuning approach for segmentation of gliomas in brain magnetic resonance images with a machine learning method to normalize image differences among facilities. Cancers. 2021; 13: 1415. https://doi.org/10.3390/cancers13061415.; Nam H., Lee H., Park J., et al. Reducing domain gap by reducing style bias. In: 2021 Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition. https://doi.org/10.48550/arXiv.1910.11645.; Yan W., Wang Y., Gu S., et al. The domain shift problem of medical image segmentation and vendor-adaptation by Unet-GAN. In: Medical Image Computing and Computer Assisted Intervention– MICCAI 2019: 22nd International Conference, Shenzhen, China, October 13–17, 2019, Proceedings, Part II. https://doi.org/10.48550/arXiv.1910.13681.; Barzekar H., Patel Y., Tong L., Yu Z. MultiNet with transformers: a model for cancer diagnosis using images. arXiv:230109007. https://doi.org/10.48550/arXiv.2301.09007.; Vaswani A., Shazeer N., Parmar N., et al. Attention is all you need. In: Advances in Neural Information Processing Systems 30 (NIPS 2017). https://doi.org/10.48550/arXiv.1706.03762.; Dosovitskiy A., Beyer L., Kolesnikov A., et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv:201011929. https://doi.org/10.48550/arXiv.2010.11929.; Liu Y., Wu Y.H., Sun G., et al. Vision transformers with hierarchical attention. arXiv:210603180. https://doi.org/10.48550/arXiv.2106.03180.; Han K., Wang Y., Chen H., et al. A survey on vision transformer. arXiv:2012.12556. https://doi.org/10.48550/arXiv.2012.12556.; Hatamizadeh A., Yin H., Heinrich G., et al. In: 2023 Global context vision transformers. arXiv:2206.09959. https://doi.org/10.48550/arXiv.2206.09959.; He K., Gan C., Li Z., et al. Transformers in medical image analysis. Intel Med. 2023; 3 (1): 59–78. https://doi.org/10.1016/j.imed.2022.07.002.; Stassin S., Corduant V., Mahmoudi S.A., Siebert X. Explainability and evaluation of vision transformers: an in-depth experimental study. Electronics. 2023; 13 (1): 175. https://doi.org/10.3390/electronics13010175.; Chetoui M., Akhloufi M.A. Explainable vision transformers and radiomics for COVID-19 detection in chest X-rays. J Clin Med. 2022; 11 (11): 3013. https://doi.org/10.3390/jcm11113013.; Dipto S.M., Reza M.T., Rahman M.N.J., et al. An XAI integrated identification system of white blood cell type using variants of vision transformer. In: Proceedings of the Second International Conference on Innovations in Computing Research (ICR’23). https://doi.org/10.1007/978-3-031-35308-6_26.; Cao Y.H., Yu H., Wu J. Training vision transformers with only 2040 images. arXiv:2201.10728. https://doi.org/10.48550/arXiv.2201.10728.; Lee S.H., Lee S., Song B.C. Vision transformer for small-size datasets. arXiv:211213492. https://doi.org/10.48550/arXiv.2112.13492.; Liu Y., Sangineto E., Bi W., et al. Efficient training of visual transformers with small datasets. arXiv:2106.03746. https://doi.org/10.48550/arXiv.2106.03746.; Fukushima K. Neocognitron: a self-organizing neural network model for a mechanism of pattern recognition unaffected by shift in position. Biol Cybernetics. 1980; 36 (4): 193–202. https://doi.org/10.1007/BF00344251.; LeCun Y., Bottou L., Bengio Y., Haffner P. Gradient-based learning applied to document recognition. Proceedings IEEE. 1998; 86 (11): 2278–324. https://doi.org/10.1109/5.726791.; Hamamoto R., Komatsu M., Takasawa K., et al. Epigenetics analysis and integrated analysis of multiomics data, including epigenetic data, using artificial intelligence in the era of precision medicine. Biomolecules. 2020; 10 (1): 62. https://doi.org/10.3390/biom10010062.; Himel G.M.S., Islam M.M., Al-Aff K.A., et al. Skin cancer segmentation and classification using vision transformer for automatic analysis in dermatoscopy-based noninvasive digital system. Int J Biomed Imaging. 2024; 2024: 3022192. https://doi.org/10.1155/2024/3022192.; https://www.pharmacoeconomics.ru/jour/article/view/1256

Διαθεσιμότητα: https://www.pharmacoeconomics.ru/jour/article/view/1256
https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.327

View record from BASE

10

Academic Journal

Artificial intelligence in oncology: global experience and future prospects ; Искусственный интеллект в онкологии: мировой опыт использования и перспективы развития

Συγγραφείς: D. I. Korabelnikov, A. I. Lamotkin, Д. И. Корабельников, А. И. Ламоткин

Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 18, No 3 (2025); 437-447 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 18, No 3 (2025); 437-447 ; 2070-4933 ; 2070-4909

Θεματικοί όροι: онкология, diagnostics, computer program, application, cancer, malignant tumors, oncology, диагностика, программа для ЭВМ, приложение, рак, злокачественные опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/1255/634; Kaul V., Enslin S., Gross S.A. History of artificial intelligence in medicine. Gastrointest Endosc. 2020; 92 (4): 807–12. https://doi.org/10.1016/j.gie.2020.06.040.; Hamamoto R., Suvarna K., Yamada M., et al. Application of artificial intelligence technology in oncology: towards the establishment of precision medicine. Cancers. 2020; 12 (12): 3532. https://doi.org/10.3390/cancers12123532.; Bhinder B., Gilvary C., Madhukar N.S., Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 2021; 11 (4): 900–15. https://doi.org/10.1158/2159-8290.CD-21-0090.; Ламоткин А.И., Корабельников Д.И., Ламоткин И.А. Искусственный интеллект: основные термины и понятия, применение в здравоохранении и клинической медицине. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2024; 17 (3): 409–15. https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.267.; Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71 (1): 7–33. https://doi.org/10.3322/caac.21654.; McKinney S.M., Sieniek M., Godbole V., et al. International evaluation of an AI system for breast cancer screening. Nature. 2020; 577 (7788): 89–94. https://doi.org/10.1038/s41586-019-1799-6.; Katzman J.L., Shaham U., Cloninger A., et al. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med Res Methodol. 2018; 18 (1): 24. https://doi.org/10.1186/s12874-018-0482-1.; Zadeh Shirazi A., Tofighi M., Gharavi A., Gomez G.A. The application of artificial intelligence to cancer research: a comprehensive guide. Technol Cancer Res Treat. 2024; 23: 15330338241250324. https://doi.org/10.1177/15330338241250324.; Itahashi K., Kondo S., Kubo T., et al. Evaluating clinical genome sequence analysis by Watson for Genomics. Front Med. 2018; 5: 305. https://doi.org/10.3389/fmed.2018.00305.; Guitton T., Allaume P., Rabilloud N., et al. Artificial intelligence in predicting microsatellite instability and KRAS, BRAF mutations from whole-slide images in colorectal cancer: a systematic review. Diagnostics. 2023; 14 (1): 99. https://doi.org/10.3390/diagnostics14010099.; Topol E.J. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25 (1): 44–56. https://doi.org/10.1038/s41591-018-0300-7.; Somashekhar S.P., Sepúlveda M.J., Puglielli S., et al. Watson for oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann Oncol. 2018; 29 (2): 418–23. https://doi.org/10.1093/annonc/mdx781.; Dacic S., Travis W.D., Giltnane J.M., et al., Artificial intelligence (AI)- powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study. J Clin Oncol. 2021; 39 (15): 106. https://doi.org/10.1200/JCO.2021.39.15_suppl.106.; Beaubier N., Tell R., Lau D., et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019; 10 (24): 2384–96. https://doi.org/10.18632/oncotarget.26797.; Coombs L., Orlando A., Wang X., et al. A machine learning framework supporting prospective clinical decisions applied to risk prediction in oncology. Digit Med. 2022; 5: 117. https://doi.org/10.1038/s41746-022-00660-3.; Bhattacharya S., Saleem S.M., Singh A., et al. Empowering precision medicine: regenerative AI in breast cancer. Front Oncol. 2024; 14: 1465720. https://doi.org/10.3389/fonc.2024.; Kim E.Y., Kim Y.J., Choi W.J., et al. Concordance rate of radiologists and a commercialized deep-learning solution for chest X-ray: real-world experience with a multicenter health screening cohort. PLoS One. 2022; 17 (2): e0264383. https://doi.org/10.1371/journal.pone.0264383.; Hussain S., Ali M., Naseem U., et al. Breast cancer risk prediction using machine learning: a systematic review. Front Oncol. 2024; 14: 1343627. https://doi.org/10.3389/fonc.2024.; Singh R.S., Masih G.D., Joshi R., et al. Chapter Five – Role of artificial intelligence in cancer diagnostics and therapeutics. In: Sobti R.C., Ganju A.K., Sobti A. (Eds) Biomarkers in cancer detection and monitoring of therapeutics. Academic Press; 2023: 83–97. https://doi.org/10.1016/B978-0-323-95116-6.00015-3.; Ламоткин А.И., Корабельников Д.И., Ламоткин И.А. и др. Искусственный интеллект в здравоохранении и медицине: история ключевых событий, его значимость для врачей, уровень развития в разных странах. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2024; 17 (2): 243–50. https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.254.; Корабельников Д.И., Ламоткин А.И. Эффективность применения искусственного интеллекта в клинической медицине. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2025; 18 (1): 114–24. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.287.; Storås A.M., Strümke I., Riegler M.A., et al. Artificial intelligence in dry eye disease. Ocul Surf. 2022; 23: 74–86. https://doi.org/10.1016/j.jtos.2021.11.004.; Xu F., Wan C., Zhao L., et al. Predicting post-therapeutic visual acuity and OCT images in patients with central serous chorioretinopathy by artificial intelligence. Front Bioeng Biotechnol. 2021; 9: 649221. https://doi.org/10.3389/fbioe.2021.649221.; Tschandl P., Codella N., Akay B.N., et al. Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic study. Lancet Oncol. 2019; 20 (7): 938–47. https://doi.org/10.1016/S1470-2045(19)30333-X.; Kann B.H., Hosny A., Aerts H. Artificial intelligence for clinical oncology. Cancer Cell. 2021; 39 (7): 916–27. https://doi.org/10.1016/j.ccell.2021.04.002.; De Silva D., Ranasinghe W., Bandaragoda T., et al. Machine learning to support social media empowered patients in cancer care and cancer treatment decisions. PLoS One. 2018; 13 (10): e0205855. https://doi.org/10.1371/journal.pone.0205855.; Abidi S.S. Knowledge management in healthcare: towards “knowledge-driven” decision-support services. Int J Med Inform. 2001; 63 (1–2): 5–18. https://doi.org/10.1016/s1386-5056(01)00167-8.; Hung C.Y., Chen H.Y., Wee L.J., et al. Deriving a novel health index using a large-scale population based electronic health record with deep networks. Annu Int Conf IEEE Eng Med Biol Soc. 2020; 2020: 5872–5. https://doi.org/10.1109/EMBC44109.2020.9176454.; Smrke U., Mlakar I., Lin S., et al. Language, speech, and facial expression features for artificial intelligence-based detection of cancer survivors' depression: scoping meta-review. JMIR Ment Health. 2021; 8 (12): e30439. https://doi.org/10.2196/30439.; Kang Y., Kim Y.J., Park S., et al. Development and operation of a digital platform for sharing pathology image data. BMC Med Inform Decis Mak. 2021; 21 (1): 114. https://doi.org/10.1186/s12911-021-01466-1.; Li J., Tian Y., Li R., et al. Improving prediction for medical institution with limited patient data: leveraging hospital-specific data based on multicenter collaborative research network. Artif Intell Med. 2021; 113: 102024. https://doi.org/10.1016/j.artmed.2021.102024.; https://www.pharmacoeconomics.ru/jour/article/view/1255

Διαθεσιμότητα: https://www.pharmacoeconomics.ru/jour/article/view/1255
https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.302

View record from BASE

11

Academic Journal

Visual impairments associated with the treatment of malignant tumors of the female reproductive system: a literature review and practical recommendations for oncogynecologists ; Зрительные нарушения при лечении злокачественных новообразований женской репродуктивной системы: обзор литературы и практические рекомендации для онкогинекологов

Πηγή: Obstetrics, Gynecology and Reproduction; Online First ; Акушерство, Гинекология и Репродукция; Online First ; 2500-3194 ; 2313-7347

Θεματικοί όροι: злокачественные опухоли репродуктивной системы, targeted therapy, immunotherapy, visual disturbances, ophthalmic complications, malignant tumors of reproductive system, таргетная терапия, иммунотерапия, зрительные нарушения, офтальмологические осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2521/1363; Даренская А.Д., Румянцев А.А., Гуторов С.Л., Тюляндина А.С. Эволюция системной лекарственной терапии диссеминированного рака эндометрия. Обзор литературы. Злокачественные опухоли. 2023;13(2):80–98. https://doi.org/10.18027/2224-5057-2023-13-2-6.; Кедрова А.Г. Иммунотерапия у больных раком шейки матки. Опухоли женской репродуктивной системы. 2020;16(2):72–7. https://doi.org/10.17650/1994-4098-2020-16-2-72-77.; Ашрафян Л.А., Киселёв В.И., Муйжнек Е.Л. и др. Современные принципы эффективной терапии рака яичников. Опухоли женской репродуктивной системы. 2015;11(2):68–75. https://doi.org/10.17650/1994-4098-2015-11-2-68-75.; Мудунов А.М., Игнатова А.В., Морозова А.С. и др. Комбинированная иммунотаргетная терапия ниволумабом и цетуксимабом: новые возможности в лечении плоскоклеточного рака головы и шеи. Опухоли головы и шеи. 2020;10(3):111–7. https://doi.org/10.17650/2222-1468-2020-10-3-111-117.; Shinde A., Panchal K., Katke S. et al A. Tyrosine kinase inhibitors as next generation oncological therapeutics: current strategies, limitations and future perspectives. Therapie. 2022;77(4):425–43. https://doi.org/10.1016/j.therap.2021.10.010.; Schneider B.J., Naidoo J., Santomasso B.D. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073–126. https://doi.org/10.1200/JCO.21.01440.; Thompson J.A., Schneider B.J,. Brahmer J. et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(4):387–405. https://doi.org/10.6004/jnccn.2022.0020.; Liu X., Wang Z., Zhao C. et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer. 2020;11(3):810–8. https://doi.org/10.1111/1759-7714.13327.; Canestraro J., Hultcrantz M., Modi S. et al. Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates. Cornea. 2022;41(6):792–801. https://doi.org/10.1097/ICO.0000000000002934.; Kim S.K., Ursell P., Coleman R.L. et al. Mitigation and management strategies for ocular events associated with tisotumabvedotin. Gynecol Oncol. 2022;165(2):385–92. https://doi.org/10.1016/j.ygyno.2022.02.010.; Coleman R.L., Lorusso D., Gennigens C. et al. Efficacy and safety of tisotumabvedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609–19. https://doi.org/10.1016/S1470-2045(21)00056-5.; Matulonis U.A., Lorusso D., Oaknin A. et al. Efficacy and safety of Mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436–45. https://doi.org/10.1200/JCO.22.01900.; Vergote I., Martin A.G., Fujiwara K. et al. LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Ann Oncol. 2023;34:S1276–S1277. https://doi.org/10.1016/j.annonc.2023.10.029.; Vergote I., Van Nieuwenhuysen E., O'Cearbhaill R.E. et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. J Clin Oncol. 2023;41(36):5536–49. https://doi.org/10.1200/JCO.23.00720.; Tisotumab Vedotin-tftv. Am J Health Syst Pharm. 2022;79(3):120–2. https://doi.org/10.1093/ajhp/zxab418.; Moore K.N., Angelergues A., Konecny G.E. et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162–74. https://doi.org/10.1056/NEJMoa2309169.; Van Gorp T., Moore K.N., Konecny G.E. et al. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximabsoravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(4):503–15. https://doi.org/10.1016/S1470-2045(25)00021-X.; Moore K.N., Oza A.M., Colombo N. et al. Phase III, randomized trial of mirvetuximabsoravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757–65. https://doi.org/10.1016/j.annonc.2021.02.017.; Farooq A.V., Esposti S.D., Popat R. et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889–911. https://doi.org/10.1007/s40123-020-00280-8.; Mirvetuximab Soravtansine-gynx. Am J Health Syst Pharm. 2023;80(7):395–7. https://doi.org/10.1093/ajhp/zxad001.; Jhaveri K.L., Wang X.V., Makker V. et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30(11):1821–30. https://doi.org/10.1093/annonc/mdz291.; Greenblatt K., Khaddour K. Trastuzumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025 Jan.; Modi S., Jacot W., Yamashita T. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.; Meric-Bernstam F., Makker V., Oaknin A. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47–58. https://doi.org/10.1200/JCO.23.02005.; Narayan P., Dilawari A., Osgood C. et al. US Food and Drug Administration Approval Summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41(11):2108–16. https://doi.org/10.1200/JCO.22.02447.; Santin A., McNamara B., Siegel E.R. et al. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. J Clin Oncol. 2023;41(16):5599.; Bardia A., Hurvitz S.A., Tolaney S.M. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–41. https://doi.org/10.1056/NEJMoa2028485.; Tagawa S.T., Balar A.V., Petrylak D.P. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85. https://doi.org/10.1200/JCO.20.03489.; Schlam I., Swain S.M. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021;7(1):56. https://doi.org/10.1038/s41523-021-00265-1.; Diver E.J., Foster R., Rueda B.R., Growdon W.B. The therapeutic challenge of targeting HER2 in endometrial cancer. Oncologist. 2015;20(9):1058–68. https://doi.org/10.1634/theoncologist.2015-0149.; National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version: 3.2025. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473. [Accessed: 12.05.2025].; Fortes B.H., Tailor P.D., Dalvin L.A. Ocular toxicity of targeted anticancer agents. Drugs. 2021;81(7):771–823. https://doi.org/10.1007/s40265-021-01507-z.; Orlandi A., Fasciani R., Cassano A. et al. Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report. BMC Cancer.2015;15:973. https://doi.org/10.1186/s12885-015-1969-3.; Saleh M., Bourcier T., Noel G. et al. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol. 2011;50(3):477–8. https://doi.org/10.3109/0284186X.2011.555781.; Huillard O., Bakalian S., Levy C. et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer. 2014;50(3):638–48. https://doi.org/10.1016/j.ejca.2013.10.016.; Swain S.M., Miles D., Kim S.B. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30. https://doi.org/10.1016/S1470-2045(19)30863-0.; Ma J., Chen W., Hu Z. et al. Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis. Invest New Drugs. 2022;40(4):861–7. https://doi.org/10.1007/s10637-022-01256-0.; Колбин А.C., Гомон Ю.М., Проскурин М.А., Балыкина Ю.Е. Эффективность применения алектиниба в сравнении с лорлатинибом у пациентов с ALK-положительным немелкоклеточным раком легкого: фармакоэкономическое исследование. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(3):412–21. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.210.; Саная С.З., Мацнева И.А., Редькина Н.А. и др. Иммуногистохимическая и молекулярная диагностика воспалительной миофибробластической опухоли матки: клиническое наблюдение и обзор литературы. Архив патологии. 2021;83(5):43–8. https://doi.org/10.17116/patol20218305143.; Malik S.M., Maher V.E., Bijwaard K.E. et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res. 2014;20(8):2029–34. https://doi.org/10.1158/1078-0432.CCR-13-3077.; Yang J.C., Liu G., Lu S. et al. Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial. J Thorac Oncol. 2023;18(12):1743–755. https://doi.org/10.1016/j.jtho.2023.08.010.; Proietti I., Skroza N., Michelini S. et al. BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel). 2020;12(7):1823. https://doi.org/10.3390/cancers12071823.; Moujaber T., Balleine R.L., Gao B. et al. New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocr Relat Cancer. 2021;29(1):R1–R16. https://doi.org/10.1530/ERC-21-0191.; Moujaber T., Etemadmoghadam D., Kennedy C.J. et al. BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition. JCO Precis Oncol. 2018;2:1–14. https://doi.org/10.1200/PO.17.00221.; Silva R., Moran B., Das S. et al. Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: a case report. Case Rep Womens Health. 2022;34:e00395. https://doi.org/10.1016/j.crwh.2022.e00395.; Lima B., Abreu M.H., Sousa S. et al. Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation. Gynecol Oncol Rep. 2022;40:100942. https://doi.org/10.1016/j.gore.2022.100942.; Mitra D., Farr M., Nagarajan P. et al. Gynecologic tract melanoma in the contemporary therapeutic era: high rates of local and distant disease progression. Gynecol Oncol. 2022;167(3):483–9. https://doi.org/10.1016/j.ygyno.2022.09.026.; Choe C.H., McArthur G.A., Caro I. et al. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831–7.e2. https://doi.org/10.1016/j.ajo.2014.07.003.; Guedj M., Quéant A., Funck-Brentano E. et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol. 2014;132(12):1421–5. https://doi.org/10.1001/jamaophthalmol.2014.3024.; Belum V.R., Rosen A.C., Jaimes N. et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2015;121(1):60–8. https://doi.org/10.1002/cncr.28980.; Tarım B., Kılıç M. Ocular side effects of Trametinib and Dabrafenib: a case report. J Ophthalmic Inflamm Infect. 2023;13(1):17. https://doi.org/10.1186/s12348-023-00339-0.; Sarny S., Neumayer M., Kofler J., El-Shabrawi Y. Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmol. 2017;17(1):146. https://doi.org/10.1186/s12886-017-0541-0.; Molero-Senosiain M., Salazar M.L., Camacho I. et al. Retinal vein occlusion in a patient on dabrafenib and trametinib therapy for metastatic melanoma. Cureus. 2022;14(8):e28372. https://doi.org/10.7759/cureus.28372.; Tewari K.S., Burger R.A., Enserro D. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317–28. https://doi.org/10.1200/JCO.19.01009.; Crowley F.J., O'Cearbhaill R.E., Collins D.C. Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer. Cancer Treat Rev. 2021;98:102225. https://doi.org/10.1016/j.ctrv.2021.102225.; Ali A., Shah A.A., Jeang L.J. et al. Emergence of ocular toxicities associated with novel anticancer therapeutics: what the oncologist needs to know. Cancer Treat Rev. 2022;105:102376. https://doi.org/10.1016/j.ctrv.2022.102376.; Adams N.J., De Alba F. Bilateral rhegmatogenous retinal detachments in a patient taking pazopanib: a case report. Am J Ophthalmol Case Rep. 2022;26:101463. https://doi.org/10.1016/j.ajoc.2022.101463.; Francis J.H., Jaben K., Santomasso B.D. et al. Immune checkpoint inhibitor-associated optic neuritis. Ophthalmology. 2020;127(11):1585–9. https://doi.org/10.1016/j.ophtha.2020.05.003.; Dalvin L.A., Shields C.L., Orloff M. et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–78. https://doi.org/10.1097/IAE.0000000000002181.; Abu-Rustum N.R., Yashar C.M., Bean S. et al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020;18(6):660–6. https://doi.org/10.6004/jnccn.2020.0027.; Abu-Rustum N., Yashar C., Arend R. et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(2):181–209. https://doi.org/10.6004/jnccn.2023.0006.; Makker V., Colombo N., Casado Herráez A. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48. https://doi.org/10.1056/NEJMoa2108330.; Lorusso D., Xiang Y., Hasegawa K. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341–50. https://doi.org/10.1016/S0140-6736(24)00317-9.; Alba-Linero C., Alba E. Ocular side effects of checkpoint inhibitors. Surv Ophthalmol. 2021;66(6):951–9. https://doi.org/10.1016/j.survophthal.2021.01.001.; Neves da Silva H.V., Placide J., Duong A. et al. Ocular adverse effects of therapeutic biologics. Ther Adv Ophthalmol. 2022;14:25158414211070878. https://doi.org/10.1177/25158414211070878.; Mirza M.R., Chase D.M., Slomovitz B.M., et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–58. https://doi.org/10.1056/NEJMoa2216334.; Tewari K.S., Monk B.J., Vergote I. et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med. 2022;386(6):544–55. https://doi.org/10.1056/NEJMoa2112187.; Francis J.H., Habib L.A., Abramson D.H. et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology. 2017;124(12):1788–98. https://doi.org/10.1016/j.ophtha.2017.05.038.; Francis J.H., Diamond E.L., Chi P. et al. MEK inhibitor-associated central retinal vein occlusion associated with hyperhomocysteinemia and MTHFR variants. Ocul Oncol Pathol. 2020;6(3):159–63. https://doi.org/10.1159/000501155.; Полянских Л.С., Петросян М.А., Морозкина С.Н., Базиян Е.В. Современные представления о селективных модуляторах рецепторов эстрогенов. Журнал акушерства и женских болезней. 2020;68(6):99–106. https://doi.org/10.17816/JOWD68699-106.; Schüler-Toprak S., Weber F., Skrzypczak M. et al. Expression of estrogen-related receptors in ovarian cancer and impact on survival. J Cancer Res Clin Oncol. 2021;147(9):2555–67. https://doi.org/10.1007/s00432-021-03673-9.; Gershenson D.M., Cobb L.P., Sun C.C. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gynecol Oncol. 2020;159(3):601–3. https://doi.org/10.1016/j.ygyno.2020.09.049.; Fernandez M.L., Dawson A., Kim H. et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Gynecol Oncol. 2020;157(1):12–20. https://doi.org/10.1016/j.ygyno.2019.11.029.; Langdon S.P., Gourley C., Gabra H., Stanley B. Endocrine therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(2):109–17. https://doi.org/10.1080/14737140.2017.1272414.; Emons G., Mustea A., Tempfer C. Tamoxifen and endometrial cancer: a janus-headed drug. Cancers (Basel). 2020;12(9):2535. https://doi.org/10.3390/cancers12092535.; Herzog T.J. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Gynecol Oncol. 2004;92(1):1–3. https://doi.org/10.1016/j.ygyno.2003.11.014.; Whitney C.W., Brunetto V.L., Zaino R.J. et al.; Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):4–9. https://doi.org/10.1016/j.ygyno.2003.09.018.; Pyrhönen S., Ellmén J., Vuorinen J. et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1999;56(2):133–43. https://doi.org/10.1023/a:1006250213357.; Gokulgandhi M.R., Vadlapudi A.D., Mitra A.K. Ocular toxicity from systemically administered xenobiotics. Expert Opin Drug Metab Toxicol. 2012;8(10):1277–91. https://doi.org/10.1517/17425255.2012.708337.; Bicer T., Imamoglu G.I., Caliskan S. et al. The effects of adjuvant tamoxifen use on macula pigment epithelium optical density, visual acuity and retinal thickness in patients with breast cancer. Curr Eye Res. 2020;45(5):623–28. https://doi.org/10.1080/02713683.2019.1687725.; Mitra S., Lami M.S., Ghosh A. et al. Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications? Cancers (Basel). 2022;14(3):759. https://doi.org/10.3390/cancers14030759.; Serban D., Costea D.O., Zgura A. et al. Ocular side effects of aromatase inhibitor endocrine therapy in breast cancer – a review. In Vivo. 2022;36(1):40–48. https://doi.org/10.21873/invivo.12674.; Almafreji I., Smith C., Peck F. Review of the literature on ocular complications associated with aromatase inhibitor use. Cureus. 2021;13(8):e17565. https://doi.org/10.7759/cureus.17565.; Liu J.F., Konstantinopoulos P.A., Matulonis U.A. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014;133(2):362–9. https://doi.org/10.1016/j.ygyno.2014.02.039.; Pratt G., Yap C., Oldreive C. et al. A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. 2018;182(3):429–33. https://doi.org/10.1111/bjh.14793.; Sakellakis M., Spathas N., Tsaousis K.T. et al. Potential ophthalmological side effects induced by anti-neoplastic regimens for the treatment of genitourinary cancers: a review. Cureus. 2022;14(7):e27266. https://doi.org/10.7759/cureus.27266.; https://www.gynecology.su/jour/article/view/2521

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/2521
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.661

View record from BASE

12

Academic Journal

Primary malignant lung tumors in children (review of the literature) ; Первичные злокачественные опухоли легких у детей (обзор литературы)

Συγγραφείς: N. G. Uskova, D. G. Akhaladze, N. S. Grachev, Н. Г. Ускова, Д. Г. Ахаладзе, Н. С. Грачев

Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 12, № 1 (2025); 48-54 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 12, № 1 (2025); 48-54 ; 2413-5496 ; 2311-1267

Θεματικοί όροι: подростки, malignant tumors, neuroendocrine lung tumor, lung carcinoid, lung cancer, pleuropulmonary blastoma, children, adolescents, злокачественные опухоли, нейроэндокринная опухоль легкого, карциноид легкого, рак легкого, плевропульмональная бластома, дети

Περιγραφή αρχείου: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/1130/985; Hartman G.E., Shochat S.J. Primary pulmonary neoplasms of childhood: a review. Ann Thorac Surg. 1983;36(1):108–19. doi:10.1016/s0003-4975(10)60664-9.; Cohen M.C., Kaschula R.O. Primary pulmonary tumors in childhood: a review of 31 years’ experience and the literature. Pediatr Pulmonol. 1992;14(4):222–32. doi:10.1002/ppul.1950140405.; Dishop M.K., Kuruvilla S. Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children’s hospital. Arch Pathol Lab Med. 2008;132(7):1079–103. doi:10.5858/2008-132-1079-PAMLTI.; An J., Han J., Ahn K.H., Kim J., Choi Y.S. Primary neoplasms of the lung in children and adolescents: 22 cases from a single institute. J Lung Cancer. 2009;8(2):103–10. doi:10.6058/jlc.2009.8.2.103.; Weldon C.B., Shamberger M.D. Pediatric pulmonary tumors: primary and metastatic. Semin Pediatr Surg. 2008;17:17–29. doi:10.1053/j.sempedsurg.2007.10.004.; Yu D.C., Grabowski M.J., Kozakewich H.P., Perez-Atayde A.R., Voss S.D., Shamberger R.C., Weldon C.B. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg. 2010;45:1090–5. doi:10.1016/j.jpedsurg.2010.02.070.; Indolfi P., Casale F., Carli M., Bisobno G., Ninfo V., Cecchetto G., Bagnulo S., Santoro N., Giuliano M., Di Tullio M.T. Pleuropulmonary blastoma: management and prognosis of 11 cases. Cancer. 2000;89:1396–401. doi:10.1002/1097-0142(20000915)89:63.0.CO;2-2.; Dehner L.P., Tazelaar H.D., Manabe T. Pleuropulmonary blastoma. In: World Health Organization classifi cation of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. (eds.). IARC Press, Lyon, 2004. Pp. 99–100.; Büyükavc M., Altas S., Salman B., Eren S. An aggressive childhood tumor mimicking pleural empyema: pleuropulmonary blastoma. J Pediatr Hematol Oncol. 2006;28(4):257–9. doi:10.1097/01.mph.0000212917.24051.6f.; Neville H.L., Hogan A.R., Zhuge Y., Perez E.A., Cheung M.C., Koniaris L.G., Thompson W.R., Sola J.E. Incidence and outcomes of malignant pediatric neoplasms. J Surg Res. 2009;156(2):224–30. doi:10.1016/j.jss.2009.03.100.; Abele M., Voggel S., Bremensdorfer C., Spix C., Erdmann F., Kuhlen M., Redlich A., Ebinger M., Lang P., Schneider D.T., Brecht I.B. Incidences and characteristics of primary lung malignancies in childhood in Germany: An analysis of population-based data from German cancer registries. Pediatr Blood Cancer. 2022;69(9):e29744. doi:10.1002/pbc.29744.; Ferrari A., Brecht I.B., Gatta G., Schneider D.T., Orbach D., Cecchetto G., Godzinski J., Reguerre Y., Bien E., Stachowicz-Stencel T., Ost M., Magni C., Kearns P., Vassal G., Massimino M., Biondi A., Bisogno G., Trama A. Defi ning and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer. 2019;110:120–6. doi:10.1016/j.ejca.2018.12.031.; Rojas Y., Shi Y.X., Zhang W., Beierle E.A., Doski J.J., Goldfarb M., Goldin A.B., Gow K.W., Langer M., Vasudevan S.A., Nuchtern J.G. Primary malignant pulmonary tumors in children: a review of the national cancer data base. J Pediatr Surg. 2015;50(6):1004–8. doi:10.1016/j.jpedsurg.2015.03.032.; Smith N.J., Mukherjee D., Wang Y., Brazauskas R., Nelson A.A., Cortina C.S. Epidemiology and outcomes of primary pediatric lung malignancies: Updates from the SEER database. Am J Surg. 2021;222(4):861–6. doi:10.1016/j.amjsurg.2021.01.037.; Demir H.A., Yalcin B., Ciftci A.O., Ciftci A.O., Orhan D., Varan A., Akyuz C., Kutluk T., Buyukpamukcu M. Primary pleuropulmonary neoplasms in childhood: fourteen cases from a single center. Asian Pac J Cancer Prev. 2011;12(2):543–7. PMID: 21545227.; Erdmann F., Kaatsch P., Grabow D., Spix C. German Childhood Cancer Registry – Annual Report 2019 (1980–2018). Institute of medical biostatistics, epidemiology and informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz. 2020;28.; Youlden D.R., Foresto S.A., Aitken J.F. Primary malignant lung tumors in children: a report from the Australian Childhood Cancer Registry, 1983–2015. Pediatr Pulmonol. 2020;55(3):719–22. doi:10.1002/ppul.24636.; Hancock B.J., DiLorenzo M., Youssef S., Yazbeck S., Marcotte J.E., Collin P.P. Childhood primary pulmonary neoplasms. J Pediatr Surg. 1993;28:1133–6. doi:10.1016/0022-3468(93)90147-d.; McCahon E. Lung tumours in children. Paediatr Respir Rev. 2006;7:191–6. doi:10.1016/j.prrv.2006.05.002.; Lal D.R., Clark I., Shalkow J., Downey R.J., Shorter N.A., Klimstra D.S., La Quaglia M.P. Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer. 2005;45:683–6. doi:10.1002/pbc.20279.; Wang L.T., Wilkins E.W., Bode H.H. Bronchial carcinoid tumors in pediatric patients. Chest. 1993;103(5):1426–8. doi:10.1378/chest.103.5.1426.; Moraes T.J., Langer J.C., Forte V., Shayan K., Sweezey N. Pediatric pulmonary carcinoid: a case report and review of the literature. Pediatr Pulmonol. 2003;35:318–22. doi:10.1002/ppul.10249.; Faurox B., Aynie V., Larroquet M., Boccon-Gibod L., Ducou le Pointe H., Tamalet A., Clement A. Carcinoid and mucoepidermoid bronchial tumors in children. Eur J Pediatr. 2005;164:748–52. doi:10.1007/s00431-005-1740-x.; Welsh J.H., Maxson T., Jaksic I., Shahab I., Hicks J. Tracheobroncial mucoepidermoid carcinoma in childhood and adolescence: a case report and review of the literature. Int J Pediatr Otorhinolaryngol. 1998;45:265–73. doi:10.1016/s0165-5876(98)00120-7.; Ramos S.G., Barbosa G.H., Tavora F.R., Jeudy J., Torres L.A.G.M., Tone L.G., Trad C.S. Bronchoalveolar carcinoma arising in a congenial pulmonary airway malformation in a child: case report with an update of this asso ciation. J Pediatr Surg. 2007;42:E1–4. doi:10.1016/j.jpedsurg.2007.02.003.; West D., Nicholson A.G., Colquhoun I., Pollock J. Bronchoalveolar carcinoma in congenital cyst adenomatoid malformation of lung. Ann Thorac Surg. 2007;83:687–9. doi:10.1016/j.athoracsur.2006.06.029.; Bartley T.D., Arean V.M. Intrapulmonary neurogenic tumors. J Thorac Cardiovasc Surg. 1965;50:114–23. PMID: 14313860.; Crist W.M., Raney R.B. Jr, Newton W., Lawrence W. Jr, Teff t M., Foulkes M.A. Intrathoracic soft tissue sarcomas in children. Cancer. 1982;50(3):598–604. doi:10.1002/1097-0142(19820801)50:33.0.co;2-#.; Jimenez J.F., Uthman E.O., Townsend J.W., Gloster E.S., Seibert J.J. Primary bronchopulmonary leiomyosarcoma in childhood. Arch Pathol Lab Med. 1986;110(4):348–51. PMID: 3754125.; Pettinato G., Manivel J.C., Saldana M.J., Peyser J., Dehner L.P. Primary bronchopulmonary fi brosarcoma of childhood and adolescence: reassessment of a low-grade malignancy. Clinicopathologic study of fi ve cases and review of the literature. Hum Pathol. 1989;20(5):463–71. doi:10.1016/0046-8177(89)90012-9.; Muwakkit S.A., Rodriguez-Galindo C., El Samra A.I., Khoury R., Akel S.R., Mroueh S., Razzouk B., Abboud M.R. Primary malignant peripheral nerve sheath tumor of the lung in a young child without neurofi bromatosis type 1. Pediatr Blood Cancer. 2006;47(5):636–8. doi:10.1002/pbc.20787.; Ferrari A., Bisogno G., Alaggio R., Cecchetto G., Collini P., Rosolsen A., Meazza C., Indolfi P., Garaventa A., De Sio L., D’Angelo P., Tamaro P., Casanova M., Carli M. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer. 2008;44(9):1202–9. doi:10.1016/j.ejca.2008.03.016.; Balaji R., Kumar P., Garg I., Das K. Primary pulmonary rhabdomyosarcoma in a child. J Indian Assoc Pediatr Surg. 2017;22(1):57–9. doi:10.4103/0971-9261.194629.; Wu X., Zhou C., Jin L., Liu H., Liu J., Zhao S. Primary pulmonary lymphoma in children. Orphanet J Rare Dis. 2019;14(1):35. doi:10.1186/s13023-019-1009-5.; Oguz B., Ozcan H.N., Omay B., Ozgen B., Haliloglu M. Imaging of childhood infl ammatory myofi broblastic tumor. Pediatr Radiol. 2015;45(11):1672–81. doi:10.1007/s00247-015-3377-x.; Travis W.D., Brambilla E., Nicholson A.G., Yatabe Y., Austin J.H.M., Beasley M.B., Chirieac L.R., Dacic S., Duhig E., Flieder D.B., Geisinger K., Hirsch F.H., Ishikawa Y., Kerr K.M., Noguchi M., Pelosi G., Powell C.A., Sound Tsao M., Wistuba I., WHO panel. The 2015 World Health Organization classifi cation of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classifi cation. J Thorac Oncol. 2015;10(9):1243–60. doi:10.1097/JTO.0000000000000630.; Messinger Y.H., Stewart D.R., Priest J.R., Williams G.M., Harris A.K., Schultz K.A.P., Yang J., Doros L., Rosenberg P.S., Hill D.A., Dehner L.P. Pleuropulmonary blastoma: a report on 350 central pathology-confi rmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer. 2015;121(2):276–85. doi:10.1002/cncr.29032.; Gelinas J.F., Manoukian J., Cote A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int J Pediatr Otorhinolaryngol. 2008;72(4):433–52. doi:10.1016/j.ijporl.2007.12.003.; Casagrande A., Pederiva F. Association between congenital lung malformations and lung tumors in children and adults: a systematic review. J Thorac Oncol. 2016;11(11):1837–45. doi:10.1016/j.jtho.2016.06.023.; Karatayli-Ozgursoy S., Bishop J.A., Hillel A., Akst L., Best S.R. Risk factors for dysplasia in recurrent respiratory papillomatosis in an adult and pediatric population. Ann Otol Rhinol Laryngol. 2016;125(3):235–41. doi:10.1177/0003489415608196.; Mai P.L., Best A.F., Peters J.A., DeCastro R.M., Khincha P.P., Loud J.T., Bremer R.C., Rosenberg P.S., Savage S.A. Risks of fi rst and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li–Fraumeni syndrome cohort. Cancer. 2016;122(23):3673–81. doi:10.1002/cncr.30248.; Niitu Y., Kubota H., Hasegawa S., Horikawa M., Komatsu S. Lung cancer (squamous cell carcinoma) in adolescence. Am J Dis Child. 1974;127:108–11. doi:10.1001/archpedi.1974.02110200110017.; La Salle A.J., Andrassy R.J., Stanfor W. Bronchogenic squamous cell carcinoma in childhood: a case report. J Pediatr Surg. 1977;12:519–21. doi:10.1016/0022-3468(77)90189-0.; Sharma R., Stein D., Khan W. Primary squamous cell carcinoma of the lung in a 7-year old boy: a case report. J Pediatr Hematol Oncol. 2011;33:e307–9. doi:10.1097/MPH.0b013e31822bf5e2.; Longhi A., Bertoni F., Bacchini P., Albisinni U., Mercati U., Bacci G. Simultaneous osteosarcoma lung metastasis and second primary lung cancer. J Pediatr Hematol Oncol. 2004;26(7):457–61. doi:10.1097/00043426-200407000-00013.; Holmqvist A.S., Chen Y., Berano Teh J.B., Sun C., Birch J.M., van des Bos C., Diller L.R., Dilley K., Ginsberg J., Martin L.T., Nagarajan R., Nathan P.C., Neglia J.P., Terenziani M., Tishler D., Meadows A.T., Robinson L.L., Oberlin O., Bhatia S. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma identifi cation of high-risk populations to guide surveillance: a report from the Late Eff ects Study Group. Cancer. 2019;125(8):1373–83. doi:10.1002/cncr.31807.; Giuseppucci C., Reusmann A., Giubergia V., Barrias C., Kruger A., Siminovich M., Botto H., Cadario M., Boglione M., Srtambach J., Barrenechea M. Primary lung tumors in children: 24 years of experience at a referral center. Pediatr Surg Int. 2016;32:451–7. doi:10.1007/s00383-016-3884-3.; Lichtenberger J.P., Biko D.M., Carter B.W., Pavio M.A., Huppmann A.R., Chung E.M. Primary lung tumors in children: radiologic-pathology correlation. Radiographics. 2018;38(7):2151–72. doi:10.1148/rg.2018180192.; Dahabreh J., Stathopouls G.P., Koutantos J., Rigatos S. Lung carcinoid tumor biology: treatment and survival. Oncol Rep. 2009;21:757–60. doi:10.3892/or_00000281.; Rizzardi G.G., Marulli L., Bortolotti F., Calabrese F., Sartori F., Rea F. Sleeve resections and bronchoplastic procedures in typical central carcinoid tumors. Thorac Cardiovasc Surg. 2008;56:42–5. doi:10.1055/s-2007-965741.; Kanemoto A., Oshiro Y., Sugahara S., Kamagata S., Hirobe S., Toma M., Okumura T., Sakurai H. Proton beam therapy for inoperable recurrence of bronchial high-grade mucoepidermoid carcinoma. Jpn J Clin Oncol. 2012;42:552–5. doi:10.1093/jjco/hys047.; Rizzardi G., Maruli G., Calabrese F., Rugge M., Rebusso A., Sartori F., Rea F. Bronchial carcinoid tumours in children: surgical treatment and outcome in a single institution. Eur J Pediatr Surg. 2009;19:228–31. doi:10.1055/s-0029-1202857.; Marty-Ane C.H., Costes V., Pujol J.L., Alauzen M., Baldet P., Mary H. Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg. 1995;59(1):78–83. doi:10.1016/0003-4975(94)00630-P.; Manchua T.N., Guerreiro-Cardoso P.F., Camargo S.M., Signori L., Andrade C.F., Schneider Moreira A.L., da Silva Moreira J., Felicetti J.C., Camargo J.J. Surgical treatment of bronchial carcinoid tumors: a single-center experience. Lung Canc. 2010;70:158–62. doi:10.1016/j.lungcan.2010.01.015.; Daddi N., Schiavon M., Filosso P.L., Cardillo G., Ambrogi M.C., De Palma A., Luzzi L., Bandiera A., Casali C., Ruff ato A., De Angelis V., Andriolo L.G., Guerrera F., Carleo F., Davini F., Urbani M., Mattioli S., Zannini P., Gotti G., Loizzi M., Puma F., Mussi A., Ricci A., Oliaro A., Rea F. Prognostic factors in a multicenter study of 247 atypical pulmonary carcinoids. Eur J Cardiothorac Surg. 2014;45:677–86. doi:10.1093/ejcts/ezt470.; Degnan A.J., Tocchio S., Kurtom W., Tadros S.S. Pediatric neuroendocrine carcinoid tumors: management, pathology, and imaging fi ndings in a pediatric referral center. Pediatr Blood Canc. 2017;64:264–77. doi:10.1002/pbc.26477.; Rizzardi G., Bertolaccini L., Terzi A. Bronchial carcinoid tumours in children – a review. Eur J Haematol. 2011;7(3):196–9. doi:10.17925/EOH.2011.07.03.196.; Balzer B.W.R., Loo C., Lewis C.R., Trahair T.N., Anazodo A.C. Adenocarcinoma of the lung in childhood and adolescence: a systematic review. J Thorac Oncol. 2018;13(12):1832–41. doi:10.1016/j.jtho.2018.08.2020.; Chin C.H., Huang C.C., Lin M.C., Chao T.Y., Liu S.F. Prognostic factors of tracheobronchial mucoepidermoid carcinoma – 15 years experience. Respirology. 2008;13:275–80. doi:10.1111/j.1440-1843.2007.01207.x.; Ferguson M.K., Landreneau R.J., Hazelrigg S.R., Altorki N.K., Naunheim K.S., Zwischenberger J.B., Kent M., Yim A.P. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18(2):156–61. doi:10.1016/s1010-7940(00)00493-0.; Techavichit P., Hicks M.J., Lopez-Terrada D.H., Quintanilla N.M., Guillerman R.P., Sarabia S.F., Sayeed J.G., Paulino A.C., Muscal J.A., Okcu M.F., Chintagumpala M. Mucoepidermoid carcinoma in children: a single institutional experience. Pediatr Blood Cancer. 2016;63(1):27–31. doi:10.1002/pbc.25681.; Grigoletto V., Tagarelli A., Atzeni C., Cecchetto G., Indolfi P., De Pasquale M.D., De Leonardis F., Coppadoro B., Sorbara S., Chiaravalli S., Ferrari A., Bisogno G. Pleuropulmonary blastoma: a report from the TREP (Tumori Rari in Eta Pediatrica) Project. Tumori. 2020;106(2):126–32. doi:10.1177/0300891619871344.; https://journal.nodgo.org/jour/article/view/1130

Διαθεσιμότητα: https://journal.nodgo.org/jour/article/view/1130
https://doi.org/10.21682/2311-1267-2025-12-1-48-54

View record from BASE

13

Academic Journal

Medical imaging and artificial intelligence in radiotherapy of malignant tumors ; Медицинская визуализация и искусственный интеллект при радиотерапии злокачественных опухолей

Συγγραφείς: G. A. Panshin, N. V. Nudnov, Г. А. Паньшин, Н. В. Нуднов

Πηγή: Medical Visualization; Принято в печать ; Медицинская визуализация; Принято в печать ; 2408-9516 ; 1607-0763

Θεματικοί όροι: радиотерапевтическое лечение, medical imaging, artificial intelligence, malignant tumors, radiotherapy treatment, медицинская визуализация, искусственный интеллект, злокачественные опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/1500/917; NCCN Clinical Practice Guidelines in Oncology (2020) Available at https://www.nccn.org/professionals/physician_gls/default.aspx#site [Accessed on 05 May 2020].; Hussein M., Heyman B.J.M., Verellen D., Nisbet A. Automation of intensity modulated radiotherapy treatment planning – a review of recent innovations. Br. J. Radiol. 2018; 91: 20180270. http://doi.org/10.1259/bjr.20180270; Barragan-Montero A., Javaid U., Valdez G. et al. Artificial intelligence and machine learning for medical imaging: a review of technologies. Phys. Med. 2021; 83: 242–256. https://doi.org/10.1016/j.ejmp.2021.04.016; Price W.N. II. Regulating Black-Box Medicine. Mich. Law. Rev. 2017; 116 (3): 421–474. https://doi.org/10.36644/mlr.116.3.regulation; Byun H., Yu S., Oh J. et al. An Assistive Role of a Machine Learning Network in Diagnosis of Middle Ear Diseases. J. Clin. Med. 2021; 10 (15): 3198. http://doi.org/10.3390/jcm10153198; Hoo VS. Radiotherapeutic methods for prostate cancer, dose escalation and brachytherapy. Clin. Oncol. 2005; 17 (7): 560–571. http://doi.org/10.1016/J.CLON.2005.07.006; Liu Z., Liu X., Guan H. et al. Development and validation of a deep learning algorithm for auto-delineation of clinical target volume and organs at risk in cervical cancer radiotherapy. Radiother. Oncol. 2020; 153: 172–179. http://doi.org/10.1016/j.radonc.2020.09.060; Li X., Chen H., Qi X. et al. H-DenseUNet: Hybrid Densely Connected UNet for Liver and Tumor Segmentation From CT Volumes. IEEE Trans. Med. Imaging. 2018; 37 (12): 2663–2674. https://doi.org/10.48550/arXiv.1709.07330; Chen L., Bentley P., Mori K. et al. DRINet for Medical Image Segmentation. IEEE Transactions on Medical Imaging. 2018; 37 (11): 2453–2462. https://doi.org/10.1109/TMI.2018.2835303; Feng C.H., Cornell M., Moore K.L. et al. Automated contouring and planning pipeline for hippocampal-avoidant whole-brain radiotherapy. Radiat. Oncol. 2020; 15 (1): 251. https://doi.org/10.1186/s13014-020-01689-y; Pan Q., Zhao L., Gu S. et al. Deep learning-based automatic hippocampal detection from MRI: geometric and dosimetric evaluation. Radiat. Oncol. 2021; 16 (1): 12. https://doi.org/10.1186/s13014-020-01724-y; Tong N., Gou S., Yang S. et al. Fully automatic multi-organ segmentation for head and neck cancer radiotherapy using shape representation model constrained fully convolutional neural networks. Med. Phys. 2018; 45 (10): 4558–4567. https://doi.org/10.1002/mp.13147; Tong N., Gou S., Yang S. et al. Fully convolutional Dance Net with form restriction and competitive training of multi-organ segmentation on CT of the head and neck and MRI with a low field of view. Med. Phys. 2019; 46 (6): 2669–2682. https://doi.org/10.1002 /mp.13553; Nelms B.E., Tomé W.A., Robinson G., Wheeler J. Variations in the contouring of organs at risk: test case from a patient with oropharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012; 82 (1): 368–378. https://doi.org/10.1016/j.ijrobp.2010.10.019; Nemoto T., Futakami N., Yagi M. et al. Efficacy evaluation of 2D, 3D U-Net semantic segmentation and atlas-based segmentation of normal lungs excluding the trachea and main bronchi. J. Radiat. Res. 2020; 61 (2): 257–264. https://doi.org/10.1093/jrr/rrz086; Wong J., Huang V., Giambattista J.A. et al. Training and Validation of Deep Learning-Based Auto-Segmentation Models for Lung Stereotactic Ablative Radiotherapy Using Retrospective Radiotherapy Planning Contours. Front. Oncol. 2021; 11: 626499. https://doi.org/10.3389/fonc.2021.626499; Men K., Geng H., Biswas T. et al. Automated Quality Assurance of OAR Contouring for Lung Cancer Based on Segmentation With Deep Active Learning. Front. Oncol. 2020; 10: 986. https://doi.org/10.3389/fonc.2020.00986; Gu H., Gan W., Zhang Q. et al. A 2D-3D hybrid convolutional neural network for autosegmentation of lung lobes in standard-thickness computed tomography scans of patients receiving radiotherapy. Biomed. Eng. Online. 2021; 20 (1): 94. https://doi.org/10.1186/s12938-021-00932-1; Liu Z., Liu F., Chen W. et al. Automatic Segmentation of Clinical Target Volumes for Post-Modified Radical Mastectomy Radiotherapy Using Convolutional Neural Networks. Front. Oncol. 2021; 10: 581347. https://doi.org/10.3389/fonc.2020.581347; Choi M.S., Choi B.S., Chung S.Y. et al. Clinical evaluation of atlas- and deep learning-based automatic segmentation of multiple organs and clinical target volumes for breast cancer. Radiother. Oncol. 2020; 153: 139–145. https://doi.org/10.1016/j.radonc.2020.09.045; Xia X., Wang J., Li Y. et al. An Artificial Intelligence-Based Full-Process Solution for Radiotherapy: A Proof of Concept Study on Rectal Cancer. Front. Oncol. 2021; 10: 616721. https://doi.org/10.3389/fonc.2020.616721; Savenije M.H.F., Maspero M., Sikkes G.G. et al. Clinical implementation of MRI-based organs-at-risk auto-segmentation with convolutional networks for prostate radiotherapy. Radiat. Oncol. 2020; 15 (1): 104. https://doi.org/10.1186/s13014-020-01528-0; Sartor H., Minarik D., Enqvist O. et al. Auto-segmentations by convolutional neural network in cervical and anorectal cancer with clinical structure sets as the ground truth. Clin. Transl. Radiat. Oncol. 2020; 25: 37-45. https://doi.org/10.1016/j.ctro.2020.09.004; Cha E., Elguindi S., Onochie I. et al. Clinical implementation of deep learning contour autosegmentation for prostate radiotherapy. Radiother. Oncol. 2021; 159: 1–7. https://doi.org/10.1016/j.radonc.2021.02.040; Ma C.Y., Zhou J.Y., Xu X.T. et al. Deep learning-based auto-segmentation of clinical target volumes for radiotherapy treatment of cervical cancer. J. Appl. Clin. Med. Phys. 2022; 23 (2): e13470. https://doi.org/10.1002/acm2.13470; Byrne M., Archibald-Heeren B., Hu Y. et al. Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time. J. Appl. Clin. Med. Phys. 2022; 23 (1): e13479. https://doi.org/10.1002/acm2.13479; Sibolt P., Andersson L.M., Calmels L. et al. Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region. Phys. Imaging Radiat. Oncol. 2020; 17: 1–7. https://doi.org/10.1016/j.phro.2020.12.004; Lawton C.A., Michalski J., El-Naqa I. et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009; 74 (2): 383–387. https://doi.org/10.1016/j.ijrobp.2008.08.002; Liang F., Qian P., Suh. et al. An abdominal, multi-organ automatic design method for online adaptive radiotherapy under magnetic resonance control: an intelligent multi-level approach to fusion. Artif. Intel. Med. 2018; 90: 34–41. https://doi.org/10.1016/j.artmed.2018.07.001; Sartor H., Minarik D., Enqvist O. et al. Auto-segmentations by convolutional neural network in cervical and anorectal cancer with clinical structure sets as the ground truth. Clin. Transl. Radiat. Oncol. 2020; 25: 37–45. https://doi.org/10.1016/j.ctro.2020.09.004; Lin D., Lapen K., Sherer M.V. et al. A Systematic Review of Contouring Guidelines in Radiation Oncology: Analysis of Frequency, Methodology, and Delivery of Consensus Recommendations. Int. J. Radiat. Oncol. Biol. Phys. 2020; 107 (4): 827–835. https://doi.org/10.1016/j.ijrobp.2020.04.011; Ohno T., Wakatsuki M., Toita T. et al. The Working Group of the Gynecological Tumor Committee of the Japanese Radiation Oncology Study Group (JROSG). Recommendations for high-risk clinical target volume definition with computed tomography for three-dimensional image-guided brachytherapy in cervical cancer patients. J. Radiat. Res. 2017; 58 (3): 341–350. https://doi.org/10.1093/jrr/rrw109; Lee A.W., Ng W.T., Pan J.J. et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother. Oncol. 2018; 126 (1): 25–36. https://doi.org/10.1016/j.radonc. 2017.10.032; Robin S., Jolicoeur M., Palumbo S. et al. Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2021; 109 (5): 1243–1253. https://doi.org/10.1016/j.ijrobp.2020.11.010; Kaidar-Person O., Vrou Offersen B., Hol S. et al. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiother. Oncol. 2019; 137: 159–166. https://doi.org/10.1016/j.radonc.2019.04.010; Niyazi M., Andratschke N., Bendszus M. et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother. Oncol. 2023; 184: 109663. https://doi.org/10.1016/j.radonc.2023.109663; Small W. Jr., Bosch W.R., Harkenrider M.M. et al. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. Int. J. Radiat. Oncol. Biol. Phys. 2021; 109 (2): 413–424. https://doi.org/10.1016/j.ijrobp.2020.08.061; Iwai Y., Nemoto M.W., Horikoshi T. et al. Comparison of CT-based and MRI-based high-risk clinical target volumes in image guided-brachytherapy for cervical cancer, referencing recommendations from the Japanese Radiation Oncology Study Group (JROSG) and consensus statement guidelines from the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC ESTRO). Jpn. J. Radiol. 2020; 38 (9): 899–905. https://doi.org/10.1007/s11604-020-00980-y; Damico N., Meyer J., Das P. et al. MECOG-ACRIN Guideline for Contouring and Treatment of Early Stage Anal Cancer Using IMRT/IGRT. Pract. Radiat. Oncol. 2022; 12 (4): 335–347. https://doi.org/10.1016/j.prro.2022.01.015.; Joskowicz L., Cohen D., Caplan N., Sosna J. Inter-observer variability of manual contour delineation of structures in CT. Eur. Radiol. 2019; 29 (3): 1391–1399. https://doi.org/10.1007/s00330-018-5695-5; Schipaanboord B., Boukerroui D., Peressutti D. et al. Can atlas-based auto-segmentation ever be perfect? Insights from extreme value theory. IEEE Trans. Med. Imaging. 2019; 38: 99–106. https://doi.org/10.1109/TMI.2018.2856464; Japanese Structure Survey of Radiation Oncology in 2019 (First Report). （2022/11/28. https://www.jastro.or.jp/medicalpersonnel/data_center/JASTRO_NSS_2019-01.pdf; Liu X., Li K.W., Yang R., Geng L.S. Review of Deep Learning Based Automatic Segmentation for Lung Cancer Radiotherapy. Front. Oncol. 2021; 11: 717039. https://doi.org/10.3389/fonc.2021.717039; Vrtovec T., Močnik D., Strojan P. et al. Auto-segmentation of organs at risk for head and neck radiotherapy planning: From atlas-based to deep learning methods. Med. Phys. 2020; 47 (9): e929–e950. https://doi.org/10.1002/mp.14320; Kneepkens E., Bakx N., van der Sangen M. et al. Clinical evaluation of two AI models for automated breast cancer plan generation. Radiat. Oncol. 2022; 17 (1): 25. https://doi.org/10.1186/s13014-022-01993-9; Li G., Wu X., Ma X. Artificial intelligence in radiotherapy. Semin. Cancer Biol. 2022; 86 (Pt 2): 160–171. https://doi.org/10.1016/j.semcancer.2022.08.005; Sumida I., Magome T., Kitamori H. et al. Deep convolutional neural network for reduction of contrast-enhanced region on CT images. J. Radiat. Res. 2019; 60 (5): 586–594. https://doi.org/10.1093/jrr/rrz030; Fh T., Cyw C., Eyw C. Radiomics AI prediction for head and neck squamous cell carcinoma (HNSCC) prognosis and recurrence with target volume approach. B.J.R. Open. 2021; 3 (1): 20200073. https://doi.org/10.1259/bjro.20200073; Bang C., Bernard G., Le W.T. et al. Artificial intelligence to predict outcomes of head and neck radiotherapy. Clin. Transl. Radiat. Oncol. 2023; 39: 100590. https://doi.org/10.1016/j.ctro.2023.100590; Liang Z.-G., Tan H.Q., Zhang F. et al. Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. Br. J. Radiol. 2019; 92 (1102): 20190271. https://doi.org/10.1259/bjr.20190271; Chen N.-B., Xiong M., Zhou R. et al. CT radiomics-based longterm survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment. Radiat. Oncol. 2022; 17 (1): 184. https://doi.org/10.1186/s13014-022-02136-w; Astaraki M., Wang C., Buizza G. et al. Early survival prediction in non-small cell lung cancer from PET/CT images using an intratumor partitioning method. Phys. Med. 2019; 60: 58–65. https://doi.org/10.1016/j.ejmp.2019.03.024; Zhang N., Liang R., Gensheimer M.F. et al. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. Theranostics. 2020; 10: 11707–10718. https://doi.org/10.7150/thno.50565; Huang Z., Hu C., Chi C. et al. An Artificial Intelligence Model for Predicting 1-Year Survival of Bone Metastases in Non-Small-Cell Lung Cancer Patients Based on XGBoost Algorithm. Biomed. Res. Int. 2020; 2020: 3462363. https://doi.org/10.1155/2020/3462363; Du R., Lee V.H., Yuan H. et al. Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study. Radiol. Artif. Intell. 2019; 1 (4): e180075. https://doi.org/10.1148/ryai.2019180075; De Felice F., Valentini V., De Vincentiis M. et al. Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy. In Vivo (Athens, Greece). 2021; 35 (6): 3355–3360. https://doi.org/10.21873/invivo.12633; Lee S., Kerns S., Ostrer H. et al. Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2018; 101 (1): 128–135. https://doi.org/10.1016/j.ijrobp.2018.01.054; Tian Z., Yen A., Zhou Z. et al. A machine-learning-based prediction model of fistula formation after interstitial brachytherapy for locally advanced gynecological malignancies. Brachytherapy. 2019; 18 (4): 530–538. https://doi.org/10.1016/j.brachy.2019.04.004; van Velzen S.G.M., Gal R., Teske A.J. et al. AI-Based Radiation Dose Quantification for Estimation of Heart Disease Risk in Breast Cancer Survivors After Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2022; 112 (3): 621–632. https://doi.org/10.1016/j.ijrobp.2021.09.008; Tabl A.A., Alkhateeb A., ElMaraghy W. et al. A Machine Learning Approach for Identifying Gene Biomarkers Guiding the Treatment of Breast Cancer. Front. Genet. 2019; 10: 256. https://doi.org/10.3389/fgene.2019.00256; Ubaldi L., Valenti V., Borgese R.F. et al. Strategies to develop radiomics and machine learning models for lung cancer stage and histology prediction using small data samples. Phys. Med. 2021; 90: 13–22. https://doi.org/10.1016/j.ejmp.2021.08.015; Kawahara D., Murakami Y., Tani S., Nagata Y. A prediction model for degree of differentiation for resectable locally advanced esophageal squamous cell carcinoma based on CT images using radiomics and machine-learning. Br. J. Radiol. 2021; 94 (1124): 20210525. https://doi.org/10.1259/bjr.20210525; Lou B., Doken S., Zhuang T. et al. An image-based deep learning framework for individualising radiotherapy dose: a retrospective analysis of outcome prediction. Lancet Digit. Health. 2019; 1 (3): e136–e147. https://doi.org/10.1016/S2589-7500(19)30058-5; Wu S., Jiao Y., Zhang Y. et al. Imaging-Based Individualized Response Prediction Of Carbon Ion Radiotherapy For Prostate Cancer Patients. Cancer Manag. Res. 2019; 11: 9121–9131. https://doi.org/10.2147/CMAR.S214020; Haak H.E., Gao X., Maas M. et al. The use of deep learning on endoscopic images to assess the response of rectal cancer after chemoradiation. Surg. Endosc. 2022; 36 (5): 3592–3600. https://doi.org/10.1007/s00464-021-08685-7; Osman S.O.S., Leijenaar R.T.H., Cole A.J. et al. Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2019; 105 (2): 448–456. https://doi.org/10.1016/j.ijrobp.2019.06.2504; Yang Z., Olshevsky D., He K. et al. Machine learning and statistical prediction of the quality of life of patients after prostate radiation therapy. Comput. Biol. Med. 2021; 129: 104127. https://doi.org/10.1016/j.compbiomed.2020.104127; Kawamura M., Kamomae T., Yanagawa M. et al. Revolutionizing radiation therapy: the role of AI in clinical practice. J. Radiat. Res. 2024; 65 (1): 1–9. https://doi.org/10.1093/jrr/rrad090; Shin J., Seo N., Baek S.-E. et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy. Radiology. 2022; 303: 351–358. https://doi.org/10.1148/radiol.211986; Shaish H., Aukerman A., Vanguri R. et al. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study. Eur. Radiol. 2020; 30: 6263–6273. https://doi.org/10.1007/s00330-020-06968-6; Cui Y., Yang X., Shi Z. et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur. Radiol. 2019; 29: 1211–1220. https://doi.org/10.1007/s00330-018-5683-9; Thompson R.F., Valdes G., Fuller C.D. et al. Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation? Radiother. Oncol. 2018; 129 (3): 421–426. https://doi.org/10.1016/j.radonc.2018.05.030; Smith M.J., Bean S. AI and Ethics in Medical Radiation Sciences. J. Med. Imaging Radiat. Sci. 2019; 50 (4, Suppl. 2): S24–S26. https://doi.org/10.1016/j.jmir.2019.08.005; https://medvis.vidar.ru/jour/article/view/1500

Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/1500
https://doi.org/10.24835/1607-0763-1500

View record from BASE

14

Academic Journal

Изменение ИК-спектров метаболитов энергетического обмена в крови крыс с гепатоцеллюлярной карциномой при воздействии гипертермии и апитоксина

Συγγραφείς: Ol’ga V. Krasnikova, Mikhail A. Shabalin, Ol’ga V. Kondrashina, Marina S. Piskunova, Anastasiya R. Kondrat’eva, Natal’ya V. Kol’tyukova, Ol’ga M. Moskovtseva

Πηγή: Журнал медико-биологических исследований, Vol 12, Iss 1, Pp 80-88 (2024)

Θεματικοί όροι: злокачественные опухоли печени, гепатоцеллюлярная карцинома, пчелиный яд, лечебная гипертермия, энергетический обмен, инфракрасная спектроскопия плазмы крови, Sports medicine, RC1200-1245, Biology (General), QH301-705.5

Περιγραφή αρχείου: electronic resource

Relation: https://journals.narfu.ru/index.php/med/article/view/1226; https://doaj.org/toc/2542-1298; https://doaj.org/toc/2687-1491

Σύνδεσμος πρόσβασης: https://doaj.org/article/2cd3dd5a1215430f98936152e5e6b0e3

View record in DOAJ

15

Academic Journal

ЭПИДЕМИОЛОГИЧЕСКАЯ СИТУАЦИЯ ПО ЗЛОКАЧЕСТВЕННЫМ ОПУХОЛЯМ МЯГКИХ ТКАНЕЙ ГОЛОВЫ И ШЕИ (ЗОМТГШ) ПО ДАННЫМ ОБРАЩАЕМОСТИ В ГУ «РЕСПУБЛИКАНСКИЙ ОНКОЛОГИЧЕСКИЙ НАУЧНЫЙ ЦЕНТР» МЗ И СЗН РЕСПУБЛИКИ ТАДЖИКИСТАН

Θεματικοί όροι: эпидемиология, epidemiology, злокачественные опухоли мягких тканей головы и шеи (ЗОМТГШ), malignant soft tissue tumours of the head and neck (MTSTHN), 3. Good health

16

Academic Journal

Genetic factors of thrombosis FII G20210A, FV G1691A (Arg506Gln) in patients with thoracoabdominal malignant tumors ; Генетические факторы тромбоза FII G20210A, FV G1691A (Arg506Gln) у больных со злокачественными опухолями торакоабдоминальной локализации

Συγγραφείς: Korolyova A.A., Gerasimov S.S., Lyubchenko L.N.

Συνεισφορές: The study was conducted without sponsorship, Исследование проведено без спонсорской поддержки

Πηγή: Advances in Molecular Oncology; Vol 11, No 1 (2024); 105-112 ; Успехи молекулярной онкологии; Vol 11, No 1 (2024); 105-112 ; 2413-3787 ; 2313-805X

Θεματικοί όροι: factor V Leiden, prothrombin G(20210)A mutation, malignant thoracoabdominal tumors, myocardial infarction, ischemic stroke, venous thromboembolism, мутация Лейдена, мутация протромбина G(20210)A, злокачественные опухоли торакоабдоминальной локализации, инфаркт миокарда, ишемический инсульт, венозный тромбоэмболизм

Περιγραφή αρχείου: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/653/342; https://umo.abvpress.ru/jour/article/view/653

Διαθεσιμότητα: https://umo.abvpress.ru/jour/article/view/653
https://doi.org/10.17650/2313-805X-2024-11-1-105-112

View record from BASE

17

Academic Journal

Outcomes of oncologic arthroplasty in children and adolescents with malignant limb tumors: a systematic review ; Исходы онкоэндопротезирования у детей и подростков при злокачественных новообразованиях конечностей: систематический обзор литературы

Συγγραφείς: Zorin V.I., Vissarionov S.V., Makarov A.Y., Rybinskikh T.S., Rodionova K.N.

Συνεισφορές: 1

Πηγή: Traumatology and Orthopedics of Russia; Vol 30, No 4 (2024); 157-167 ; Травматология и ортопедия России; Vol 30, No 4 (2024); 157-167 ; 2542-0933 ; 2311-2905 ; 10.17816/2311-2905-2024-30-4

Θεματικοί όροι: arthroplasty, oncologic arthroplasty, malignant tumors, children, periprosthetic fractures, periprosthetic infection, эндопротезирование, онкопротезирование, злокачественные опухоли, дети, перипротезные переломы, перипротезная инфекция

Περιγραφή αρχείου: application/pdf

Διαθεσιμότητα: https://journal.rniito.org/jour/article/view/17569
https://doi.org/10.17816/2311-2905-17569

View record from BASE

18

Academic Journal

Genetic and epigenetic predictors of tongue squamous cell carcinoma sensitivity to platinum drugs ; Генетические и эпигенетические предикторы чувствительности плоскоклеточного рака языка к препаратам платины

Συγγραφείς: Kit O.I., Engibaryan M.A., Gvaramiya A.K., Volkova V.L., Chertova N.A., Kutilin D.S.

Συνεισφορές: 0

Πηγή: Annals of the Russian academy of medical sciences; Vol 79, No 6 (2024); 490-506 ; Вестник Российской академии медицинских наук; Vol 79, No 6 (2024); 490-506 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.796

Θεματικοί όροι: malignant tumors of the tongue, bioinformatics analysis, gene expression, copy number, sensitivity to platinum preparations, злокачественные опухоли языка, биоинформатический анализ, экспрессия генов, копийность, чувствительность к препаратам платины

Περιγραφή αρχείου: application/pdf

Διαθεσιμότητα: https://vestnikramn.spr-journal.ru/jour/article/view/2337
https://doi.org/10.15690/vramn2337

View record from BASE

19

Academic Journal

Electrocardiogram abnormalities in patients with hematological malignancies before and after high dose chemotherapy and autologous hematopoietic stem cell transplantation ; Изменения электрокардиограммы у пациентов с гематологическими злокачественными опухолями до и после высокодозной химиотерапии с трансплантацией аутологичных гемопоэтических стволовых клеток

Συγγραφείς: Potemkina N.A., Glezer M.G., Chomakhidze P.S., Zeynalova P.A., Petrova G.D., Novikova A.I., Gasymov A.N., Poltavskaya M.G.

Συνεισφορές: 0

Πηγή: Almanac of Clinical Medicine; Vol 52, No 2 (2024); 55-65 ; Альманах клинической медицины; Vol 52, No 2 (2024); 55-65 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: autologous hematopoietic stem cell transplantation, autoHSCT, hematological malignancies, cardiovascular toxicity, electrocardiogram, ECG, QTc prolongation, P wave abnormality, ST-T segment abnormality, high dose chemotherapy, prospective cohort study, трансплантация аутологичных гемопоэтических стволовых клеток, аутоТГСК, гематологические злокачественные опухоли, ГЗО, кардиоваскулотоксичность, электрокардиограмма, ЭКГ, удлинение QTc, изменение зубца P, нарушение сегмента ST–T, высокодозная химиотерапия, проспективное когортное исследование